BioSpace News Archive

BioCorRx Inc. is pleased to announce that it has completed its clinical trial agreement with Orange County Research Center for its first-in-human clinical trial of BICX104.

Biovica, active in cancer diagnostics, announces that the positive DiviTum®TKa results from the European multicenter study PYTHIA have been published in the highly ranked peer-reviewed scientific journal European Journal of Cancer.

TearSolutions, Inc. announced that in late 2021 it received official minutes from a Type C meeting with the U.S. Food and Drug Administration regarding the development of Lacripep for the treatment of keratoconjunctivitis sicca, also known as DED, and is planning to begin one of two phase III trials.

JN Nova Pharma is a private Canadian biotech company which has worked with an interdisciplinary team of researchers from the National Research Council of Canada’s Human Health Therapeutics Research Centre over the past year to develop a promising anti-COVID-19 biotherapeutic with enhanced protection for vulnerable patients.

Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, announced that the Company expects to report fourth quarter and record full-year 2021 preliminary unaudited total revenue of $7.2 million and $54.5 million, respectively.

Motus GI Holdings, Inc. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for the Pure-Vu® EVS System.

Oncology Pharma, Inc. announced that they intend to work jointly to fast track the development of therapeutic uses related to treatment in humans with pancreatic cancer of Regen’s patented ANTIGEN SPECIFIC MRNA CELLULAR CANCER VACCINES.

Cidara Therapeutics, Inc. (Nasdaq: CDTX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application for its lead flu drug-Fc conjugate (DFC), CD388 – a highly potent, long-acting antiviral immunotherapy designed to deliver universal prevention and treatment of seasonal and pandemic influenza.

Alpha Teknova, Inc., a leading provider of critical reagents for the development and production of biopharmaceutical products, including drug therapies, novel vaccines, and molecular diagnostics, announced that the Company will participate in the following upcoming investor conference.

UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], today announced that 24-week clinical data from the Phase 1 study of UBX1325 was presented by Robert Bhisitkul, M.D., Ph.D., professor of ophthalmology and director of the Retina Fellowship at University of California, San Francisco, at the Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 conference on Saturday, February 12, 2022.